OMNIQ Corp. OMQS OTC · Technology · United States
$0.11 +2.49% +$0.00
Summary
35 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
What to watch
- Revenue fell by 32% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It missed profit estimates 6 times in the last 8 quarters.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 9.8% a year over 5 years. Over the last 3 years it fell by 32% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $2.29M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- ISRAEL 96%
- UNITED STATES 4.2%
ISRAEL brings in 96% of revenue.
Segments in detail